Early real-world implant experience with a helix-fixation ventricular leadless pacemaker.
Aveir
Helix fixation
Implant procedure
Leadless pacemaker
Pacemaker complications
Single-chamber pacemaker
Journal
Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing
ISSN: 1572-8595
Titre abrégé: J Interv Card Electrophysiol
Pays: Netherlands
ID NLM: 9708966
Informations de publication
Date de publication:
20 Mar 2024
20 Mar 2024
Historique:
received:
11
01
2024
accepted:
13
03
2024
medline:
21
3
2024
pubmed:
21
3
2024
entrez:
21
3
2024
Statut:
aheadofprint
Résumé
Roughly one in six patients receiving conventional transvenous pacemaker systems experience significant complications within 1 year of implant, mainly due to the transvenous lead and subcutaneous pocket. A new helix-fixation single-chamber ventricular leadless pacemaker (LP) system capable of pre-deployment exploratory electrical mapping is commercially available. Such an LP may mitigate complications while streamlining the implantation. In this study, the initial real-world implant experience of the helix-fixation LP was evaluated following its commercial release. In patients indicated for single-chamber right ventricular pacing, helix-fixation Aveir VR LPs (Abbott, Abbott Park, IL) were implanted using the dedicated loading tool, introducer, and delivery catheter. Implant procedural characteristics, electrical parameters, and any 30-day procedure-related adverse events of consecutive implant attempts were retrospectively evaluated. A total of 167 patients with Class I indication for permanent pacing received implants in four North American centers (57% male, 70 years old). Pre-fixation electrical mapping of potential sites allowed repositioning to be avoided in 95.7% of patients. Median [interquartile range] LP procedure and fluoroscopy durations were 25.5 min [20.0, 35.0] and 5.7 min [4.0, 9.2], respectively. Pacing capture threshold, sensed R-wave amplitude, and impedance were 0.8 V [0.5, 1.3], 9.0 mV [6.0, 12.0], and 705 Ω [550, 910], respectively. Implantation was successful in 98.8% of patients, with 98.2% free from acute adverse events. The initial, real-world experience of the helix-fixation ventricular leadless pacemaker demonstrated safe and efficient implantation with minimal repositioning, viable electrical metrics, and limited acute complications.
Sections du résumé
BACKGROUND
BACKGROUND
Roughly one in six patients receiving conventional transvenous pacemaker systems experience significant complications within 1 year of implant, mainly due to the transvenous lead and subcutaneous pocket. A new helix-fixation single-chamber ventricular leadless pacemaker (LP) system capable of pre-deployment exploratory electrical mapping is commercially available. Such an LP may mitigate complications while streamlining the implantation. In this study, the initial real-world implant experience of the helix-fixation LP was evaluated following its commercial release.
METHODS
METHODS
In patients indicated for single-chamber right ventricular pacing, helix-fixation Aveir VR LPs (Abbott, Abbott Park, IL) were implanted using the dedicated loading tool, introducer, and delivery catheter. Implant procedural characteristics, electrical parameters, and any 30-day procedure-related adverse events of consecutive implant attempts were retrospectively evaluated.
RESULTS
RESULTS
A total of 167 patients with Class I indication for permanent pacing received implants in four North American centers (57% male, 70 years old). Pre-fixation electrical mapping of potential sites allowed repositioning to be avoided in 95.7% of patients. Median [interquartile range] LP procedure and fluoroscopy durations were 25.5 min [20.0, 35.0] and 5.7 min [4.0, 9.2], respectively. Pacing capture threshold, sensed R-wave amplitude, and impedance were 0.8 V [0.5, 1.3], 9.0 mV [6.0, 12.0], and 705 Ω [550, 910], respectively. Implantation was successful in 98.8% of patients, with 98.2% free from acute adverse events.
CONCLUSIONS
CONCLUSIONS
The initial, real-world experience of the helix-fixation ventricular leadless pacemaker demonstrated safe and efficient implantation with minimal repositioning, viable electrical metrics, and limited acute complications.
Identifiants
pubmed: 38509402
doi: 10.1007/s10840-024-01791-1
pii: 10.1007/s10840-024-01791-1
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Cantillon DJ, et al. Complications and health care costs associated with transvenous cardiac pacemakers in a nationwide assessment. JACC: Clinical Electrophysiology. 2017;3(11):1296–305.
pubmed: 29759627
Kirkfeldt RE, Johansen JB, Nohr EA, Jorgensen OD, Nielsen JC. Complications after cardiac implantable electronic device implantations: an analysis of a complete, nationwide cohort in Denmark. Eur Heart J. 2014;35(18):1186–94.
doi: 10.1093/eurheartj/eht511
pubmed: 24347317
Udo EO, et al. Incidence and predictors of short- and long-term complications in pacemaker therapy: the FOLLOWPACE study. Heart Rhythm. 2012;9(5):728–35.
doi: 10.1016/j.hrthm.2011.12.014
pubmed: 22182495
Tobin K, Stewart J, Westveer D, Frumin H. Acute complications of permanent pacemaker implantation: their financial implication and relation to volume and operator experience. Am J Cardiol. 2000;85(6):774–6.
doi: 10.1016/S0002-9149(99)00861-9
pubmed: 12000060
Sattar Y, et al. Complications of leadless vs conventional (lead) artificial pacemakers – a retrospective review. J Community Hosp Intern Med Perspect. 2020;10(4):328–33.
doi: 10.1080/20009666.2020.1786901
pubmed: 32850090
pmcid: 7427453
Tjong FVY, Reddy VY. Permanent leadless cardiac pacemaker therapy: a comprehensive review. Circulation. 2017;135(15):1458–70.
doi: 10.1161/CIRCULATIONAHA.116.025037
pubmed: 28396380
Reddy VY, et al. Primary results on safety and efficacy from the LEADLESS II-phase 2 worldwide clinical trial. JACC Clin Electrophysiol. 2022;8(1):115–7.
doi: 10.1016/j.jacep.2021.11.002
pubmed: 34863657
Roberts PR, et al. A leadless pacemaker in the real-world setting: the micra transcatheter pacing system post-approval registry. Heart Rhythm. 2017;14(9):1375–9.
doi: 10.1016/j.hrthm.2017.05.017
pubmed: 28502871
Reddy VY, et al. 1-year outcomes of a leadless ventricular pacemaker: the LEADLESS II (phase 2) trial. JACC Clin Electrophysiol. 2023;9(7 Pt 2):1187–9.
doi: 10.1016/j.jacep.2023.01.031
pubmed: 36951813